

1 10. The method of treatment defined in claim 9 wherein
2 the plasma homocysteine reducing agent is a compound selected from
3 the group consisting of folic acid, Vitamin B₆, Vitamin B₁₂, beta-
4 ine, choline, acetylcysteine, or a metabolic precursor, analogue or
5 derivative thereof.

1 11. The method of treatment defined in claim 9 wherein
2 the compound effective to reduce the elevated blood homocysteine
3 level is folic acid.

1 12. The method of treatment defined in claim 9 wherein
2 the compound effective to reduce the elevated blood homocysteine
3 level is Vitamin B₆.

1 13. The method of treatment defined in claim 9 wherein
2 the gestagen hormone composition contains a progesterone or an
3 analogue, derivative or metabolic precursor thereof.

1 14. The method of treatment defined in claim 9 wherein
2 the patient is taking a gestagen hormone composition for birth
3 control.

1 15. A method of reducing a risk of thromboembolism
2 induced by a gestagen hormone upon administration of said hormone
3 for contraception, hormone replacement therapy, relieving inflamma-
4 tion, an in vitro fertilization program, dermatological therapy or

5 cosmetological treatment in a patient comprising the step of
6 administering to the patient simultaneously, previously or subse-
7 quently to taking the gestagen hormone composition a therapeuti-
8 cally effective amount of a plasma homocysteine reducing agent.

1 16. The method of reducing a risk of thromboembolism
2 defined in claim 15 wherein the plasma homocysteine reducing agent
3 is a compound selected from the group consisting of folic acid,
4 Vitamin B₆, Vitamin B₁₂, betaine, choline, acetylcysteine, or a
5 metabolic precursor, analogue or derivative thereof.

1 17. Use of a plasma homocysteine content reducing agent
2 for the preparation of a composition comprising a gestagen type
3 hormone for reduction of a thromboembolitic side effect risk
4 induced by administration of the hormone.

1 *Al* 18. Use of a plasma homocysteine content reducing agent
2 in combination with a gestagen type hormone for the manufacture of
3 a medicament for contraception, hormone replacement therapy,
4 relieving inflammation, an in vitro fertilization program, dermato-
5 logical therapy or cosmetological treatment. --

REMARKS

This preliminary amendment is submitted in order to make
of record new claims which more sharply focus on the subject matter